Press Release: InFlectis BioScience : InFlectis BioScience Granted Orphan Drug Designation for IFB-088 (icerguastat), a Clinical Stage Treatment for Amyotrophic Lateral Sclerosis

Nantes, France--(Newsfile Corp. - March 28, 2022) - InFlectis BioScience received Orphan-Drug Designation from the U.S. Food and Drug Administration (FDA) for its investigational treatment for Amyotrophic Lateral Sclerosis (ALS), IFB-088. In preclinical studies, IFB-088 has been shown to prolong the protective effect of the Integrated Stress Response, giving cells additional time to repair or eliminate mis-folded proteins that...